Chi-Med Approved to Market Surufatinib for Neuroendocrine Tumors
December 30, 2020 at 07:05 AM EST
Hutchison China MediTech (Chi-Med) announced surufatinib was approved in China to treat non-pancreatic neuroendocrine tumors (NETs). Surufatinib has a dual mechanism, inhibiting angiogenesis and promoting tumor-associated macrophages. Chi-Med expects it will have synergistic effects when paired with other immunotherapies. Surufatinib, which will be marketed in China under the brand name Sulanda ®, is the second Chi-Med product to reach commercialization. The first was fruquintinib in 2018, marketed as Elunate ® , a treatment for colorectal cancer. More details.... Stock Symbols: (NSDQ/AIM: HCM) Share this with colleagues: // //